72 results on '"Svensson, Å"'
Search Results
2. Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia
3. Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study
4. Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine
5. Sodium nitroprusside enhances the antipsychotic-like effect of olanzapine but not clozapine in the conditioned avoidance response test in rats
6. Prefrontal NMDA receptor antagonism reduces impairments in pre-attentive information processing
7. Cost of disorders of the brain in Europe 2010
8. The size and burden of mental disorders and other disorders of the brain in Europe 2010
9. Alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors are involved in mediating the ghrelin-induced locomotor stimulation and dopamine overflow in nucleus accumbens
10. Enhancement of the antipsychotic effect of risperidone by sodium nitroprusside in rats
11. Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses
12. P.0764 Lumateperone increases glutamate release in the rat medial prefrontal cortex
13. The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism
14. Effects of acute and chronic electroconvulsive stimuli on cAMP and cGMP efflux in the rat striatum and hippocampus
15. Effects of antipsychotic drugs on cholecystokinin and preprotachykinin (substance P) mRNA expression in the rat hippocampal formation
16. Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT 2A and α 1-adrenoceptor antagonism
17. P.584 The actions of lumateperone and single nucleotide polymorphism (SNP) converge on the glutamate-NO-cGMP pathway
18. Ketamine-like effects of a combination of olanzapine and fluoxetine on AMPA and NMDA receptor-mediated transmission in the medial prefrontal cortex of the rat
19. Sodium nitroprusside but not molsidomine may be used for antipsychotic augmentation in treatment resistant schizophrenia
20. Functional mode of action of ASP5736, a selective 5-HT5A receptor antagonist for treatment of cognitive dysfunction in schizophrenia
21. Norepinephrine transporter occupancy of venlafaxine in patients with major depressive disorder using positron emission tomography and [18F]FMeNER-D2
22. P.3.c.004 - Rapid augmentation of antipsychotic drugs by sodium nitroprusside (SNP) – behavioural assessment and effect on brain dopaminergic transmission in rats
23. P.2.026 - Rapid augmentation of antipsychotic drugs by sodium nitroprusside: behavioural assessment and effect on brain dopaminergic transmission in rats
24. P.1.g.068 - Less dyskinesia at motor-equivalent doses of triple-deuterated L-DOPA vs. L-DOPA after chronic administration in rats
25. P.1.g.039 - The novel atypical antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism
26. P.3.d.031 Antipsychotic treatment in schizophrenia and related psychosis, real life data analysis of oral and long acting antipsychotics
27. Effects of phencyclidine on acoustic startle and prepulse inhibition in neuronal nitric oxide synthase deficient mice
28. P.1.g.085 Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia – a 1-year non-interventional study
29. P.3.b.003 Characterization of [3H]-LY508869 – a novel selective metabotropic glutamate 2 positive allosteric potentiator ligand
30. P.2.d.016 Add-on administration of olanzapine to fluoxetine facilitates cortical AMPA receptor-mediated responses like ketamine and scopolamine
31. Corrigendum to “Cost of disorders of the brain in Europe 2010” [Eur. Neuropsychopharmacol. 21 (2011) 718–779]
32. P.1.002 Role of 5-HT2A-receptor and α2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow
33. P.4.015 Reboxetine augments the antipsychotic-like effect of quetiapine and enhances cortical dopamine output and NMDA-induced currents
34. Mode of action of atypical antipsychotic drugs
35. P.3.d.015 Enhanced cortical dopaminergic and glutamatergic transmission and antipsychotic-like effect of risperidone by idazoxan
36. P.3.c.074 L-lysine as an add-on treatment in patients with schizophrenia
37. P.3.d.013 Reboxetine enhances cortical dopaminergic and glutamatergic transmission and the antipsychotic-like effect of olanzapine
38. P.3.d.016 Effects of asenapine on prefrontal NMDA receptor-mediated transmission: involvement of dopamine D1 receptors
39. P.3.d.022 Asenapine-induced effects on cortical monoaminergic projections
40. P.3.d.007 Asenapine: preclinical evidence for clinical effects in schizophrenia and cognitive dysfunction
41. S.08.02 Animal models for the assessment of cognitive dysfunctions in schizophrenia: focus on the nitric oxide pathway
42. P.2.19 Cortical cholinergic deficiency enhances amphetamine-induced dopamine release in accumbens but not in striatum
43. P.1.38 Adjuvant treatment with the anticonvulsant drug topiramate in schizophrenia
44. P.1.23 Asenapine: preclinical evidence for clinical effects in Schizophrenia
45. Inhibition of glycine uptake augments risperidone's effect on prefrontal glutamatergic transmission
46. P.2.15 Kynurenic acid andN-acetylaspartylglutamate do not alter PPI in mice
47. P.1.25 Galantamine increases firing activity of dopaminergic neurons in the ventral tegmental area
48. S.15.01 Mode of action of atypical antipsychotic drugs:Focus on α 2 adrenoceptors
49. P.4.17 Pharmacological effects of phencyclidine: dependence on cGMP signaling
50. P.2.21 Phencyclidine increases prepulse inhibition of acoustic startle in neuronal nitric oxide synthase deficient mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.